2 The HIV/AIDS has a market of about 12 to15 Billion US Dollars per year.
Approximately 30% or more of the HIV/AIDS population falls in the salvage category, identifying them as being resistant to one or more Anti Retroviral Drugs due to viral mutation. Our research to date suggests that Immunotech’s ITV-1 shows no viral resistance, making it well positioned to target this market niche.

3 ITV-1 works by acting as a:
(a) Fusion Inhibitor (b) Entry Inhibitor (c) Immunomodulator
Immunotech’s technology indicates to be first of it’s kind, first to market.

4 Research to date suggests minimal to zero toxicity levels to ITV-1, with minor side effects.

5 Immunotech’s management is in preparation to initiate discussions with the Food and Drug Administration (FDA) to grant fast track status to ITV-1, accelerating market entry upon such approval.

6 ITV-1 treatment regimen is more simple then current treatment modalities, having two cycles of eight weeks each, with 2 intramuscular injections per week, for a total of 32 injections. The patient will then be treated with a one eight week cycle every 6 months.

7 A simple treatment as is the case with ITV-1, also results in cost savings both on the individual and governmental levels.

8 ITV-1 research findings suggest improved quality of life.

9 Immunotech has currently in research three additional candidates in its product pipeline:
- Treatment for Prenatal HIV/AIDS
- Treatment for Pediatric HIV/AIDS
- Preventive AIDS Vaccine